Treatment for mild cognitive impairment: systematic review.

Claudia Cooper, Ryan Li, Constantine Lyketsos, Gill Livingston

Journal: The British journal of psychiatry : the journal of mental science 2014;203(3):255-64

PMID: 24085737

Free Full Text on PubMed Central View on PubMed

Abstract

BACKGROUND

More people are presenting with mild cognitive impairment (MCI), frequently a precursor to dementia, but we do not know how to reduce deterioration.

AIMS

To systematically review randomised controlled trials (RCTs) evaluating the effects of any intervention for MCI on cognitive, neuropsychiatric, functional, global outcomes, life quality or incident dementia.

METHOD

We reviewed 41 studies fitting predetermined criteria, assessed validity using a checklist, calculated standardised outcomes and prioritised primary outcome findings in placebo-controlled studies.

RESULTS

The strongest evidence was that cholinesterase inhibitors did not reduce incident dementia. Cognition improved in single trials of: a heterogeneous psychological group intervention over 6 months; piribedil, a dopamine agonist over 3 months; and donepezil over 48 weeks. Nicotine improved attention over 6 months. There was equivocal evidence that Huannao Yicong improved cognition and social functioning.

CONCLUSIONS

There was no replicated evidence that any intervention was effective. Cholinesterase inhibitors and rofecoxib are ineffective in preventing dementia. Further good-quality RCTs are needed and preliminary evidence suggests these should include trials of psychological group interventions and piribedil.

Address: Claudia Cooper, MRCPsych, PhD, Ryan Li, BSc, Mental Health Sciences Unit, University College London, UK; Constantine Lyketsos, MD, MHS, Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine and Johns Hopkins Bayview, Johns Hopkins Medicine, Baltimore, Maryland, USA; Gill Livingston, FRCPsych, MD, Mental Health Sciences Unit, University College London, UK.

DOI: 10.1192/bjp.bp.113.127811